Brief: PureTech Health's Seaport Therapeutics Begins Phase 1 Trial of GlyphAgo; Advances Second Clinical Candidate

Puretech Health

11/09/2025 12:16

Sept 11 (Reuters) - PureTech Health PLC PRTC.L:

PURETECH FOUNDED ENTITY SEAPORT THERAPEUTICS ADVANCES SECOND THERAPEUTIC CANDIDATE INTO CLINICAL DEVELOPMENT WITH DOSING OF FIRST PARTICIPANT IN PHASE 1 STUDY OF GLYPHAGO™ (SPT-320) IN HEALTHY VOLUNTEERS

Source text: ID:nBw539CBXa

Further company coverage: PRTC.L

 ((Reuters.Briefs@thomsonreuters.com;))